Global HIV Vaccine Enterprise Announces New Collaboration with the International AIDS Society (IAS)

The Global HIV Vaccine Enterprise has announced that it will partner with IASthe world’s largest association of HIV professionals, to host the operations of the Enterprise into the future.  The Global HIV Vaccine Enterprise promotes coordination, collaboration and resource mobilization to accelerate the development of preventive HIV vaccines.

While the Enterprise has operated as a free-standing organization since its founding in 2005, a recent strategic review, which involved consultations with leaders in academia, industry and advocacy for HIV vaccine development, found that the Enterprise could carry out its mission more efficiently and effectively by partnering with a suitable host organization.  IAS was selected from among a number of highly qualified organizations that applied to host the Enterprise through a process announced by the Enterprise board in May 2017.

Under the new arrangement, the Enterprise will continue to support efforts to expand, enhance and speed HIV vaccine research.  IAS will host and administer the Enterprise programs and help to expand the impact of these initiatives through its global network of HIV professionals.  In addition, IAS will support the biennial HIV Research for Prevention (HIVR4P) conference, the world’s first and only scientific meeting dedicated exclusively to biomedical HIV prevention, which will take place in Madrid, 21-25 October 2018.

Gerald Voss, interim director of the Global HIV Vaccine Enterprise, said: “Since its founding, the Enterprise has supported the field and facilitated its progress through a period marked by major scientific advances, the creation of multiple vaccine development centers and consortia and a significant expansion of vaccine research capacity, especially in developing countries.  In addition, the Enterprise-led HIVR4P conference has created a critical platform to accelerate HIV prevention research collaborations.  We expect to expand that track record of accomplishments through this new affiliation with IAS.”

“We look forward to making this partnership a reality,” said IAS Executive Director Owen Ryan. “As we work together, our shared goal is to combine our efforts to increase support for researchers, scientists and advocates working to develop an effective HIV vaccine.”

IAS and the Enterprise are working now to ensure a smooth transition into the new partnership.  Operational details of the collaboration will be announced in the months ahead.



Contacts:
Mark Aurigemma                                                                                      
Global HIV Vaccine Enterprise                      
+1 646 270 9451                                                                    
mark@aucomm.net                                                             
                                                                      
About the Global HIV Vaccine Enterprise
The Global HIV Vaccine Enterprise is an alliance of independent organizations founded to address a broad scientific consensus in support of a global effort to coordinate HIV vaccine research.  The Enterprise works to accelerate the development of a preventive HIV vaccine through advocacy for increased resources for vaccine research and development, and programming to increase coordination, collaboration and knowledge sharing across the field.


# # #





Comments

Popular posts from this blog

Hacked To Death: Kawere Fahad 21 Years Dies From His Wounds

Q And A Forum: 20 AIDS Do's Is And Was!

Q And A Forum: What is Four On Food ?